GLP-1 Awareness Reaches 92% Among Americans as Interest Outpaces Adoption, Study
Krissy Vann | Host, All Things Fitness and Wellness
A new study from Reach3 Insights highlights how quickly GLP-1 medications have entered the mainstream, with awareness now nearly universal across the US.
According to the firm’s “Beyond Weight Loss” report, 92% of Americans are familiar with GLP-1 drugs. However, only 13% report current use, while 38% of non-users say they are interested in trying them. The gap between awareness and adoption points to continued runway for growth, with barriers such as cost, access, and insurance coverage likely limiting uptake.
The findings suggest that the impact of GLP-1s extends beyond weight loss. Users report changes in their relationship with food, including reduced cravings, less constant hunger, and a greater sense of control over eating habits.
Behavioral shifts are also emerging. Among current users, 65% say they are taking GLP-1s for weight loss, 57% report eating smaller portions, and 44% say they experience fewer cravings for junk food. One in four users report eating out less often and opting for low or no sugar beverages more frequently.
These changes are starting to influence spending patterns beyond healthcare, particularly across food and beverage categories.
The study also points to a disconnect between expectations and real-world outcomes. While 77% of those interested in GLP-1s expect weight loss alongside improved energy and overall well-being, some current users report mixed results or side effects, reinforcing the need for education and more personalized approaches to care.
The research is part of Reach3’s ongoing Digital Health Trends series, which tracks how consumer attitudes evolve as new health technologies become more widely adopted.
Based on a survey of 1,043 US adults, the data underscores a category still early in its adoption curve but already reshaping how consumers think about food, health, and daily routines.
